Increased EGFR/c-Met signaling in lung cancer patients is associated with shorter survival, suggesting that the interplay between EGFR and c-Met signaling plays a crucial role in lung tumor progression and development of resistance to TKI treatments [8]. This evidence concerns the gene EGFR and lung carcinoma.